Brought to you by 
Janssen gets rights to Evotec/Harvard's diabetes compounds; deal terminated
07 Dec 2015
Executive Summary
Johnson & Johnson’s Janssen Pharmaceuticals Inc. has licensed exclusive rights to drug discovery company Evotec AG’s group of small molecules and biologics that trigger the regeneration of insulin-producing beta cells.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Janssen gets rights to Evotec/Harvard's diabetes compounds; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice